Insight
Healthcare and life sciences will face continued disruption in 2018 as new technologies, economic pressures and consumer/patient demands change the industry.
KPMG and Leavitt Partners surveyed 265 corporate finance professionals about their thoughts about the industry and 12 separate sub-sectors. While some fear a market bubble from the lofty valuations seen in some transactions, many see continued growth, investment and merger activity. Beyond the survey results, the 2018 Healthcare and Life Sciences Investment Summary looks at healthcare policy and key disrupters that are reshaping more than one-sixth of the U.S. economy.
The 2018 Healthcare and Life Sciences Investment Summary looks at healthcare policy and key disrupters that are reshaping more than one-sixth of the U.S. economy.
Related content
KPMG Healthcare & Life Sciences Institute
Register to receive timely insights
Register to receive timely insights
Subscribe now
About Healthcare & Life Sciences at KPMG
Our practice
Our capabilities
Meet our team